BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 14696059)

  • 1. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
    Narath R; Lörch T; Rudas M; Ambros PF
    Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
    Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
    Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatic telomere length measurements in interphase nuclei by IQ-FISH.
    Narath R; Lörch T; Greulich-Bode KM; Boukamp P; Ambros PF
    Cytometry A; 2005 Dec; 68(2):113-20. PubMed ID: 16228977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid fluorescence in situ hybridization with repetitive DNA probes: quantification by digital image analysis.
    Celeda D; Aldinger K; Haar FM; Hausmann M; Durm M; Ludwig H; Cremer C
    Cytometry; 1994 Sep; 17(1):13-25. PubMed ID: 8001456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.
    Valent A; Guillaud-Bataille M; Farra C; Lozach F; Spengler B; Terrier-Lacombe MJ; Valteau-Couanet D; Danglot G; Lenoir GM; Brison O; Bénard J; Bernheim A
    Cancer Genet Cytogenet; 2004 Aug; 153(1):10-5. PubMed ID: 15325088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections.
    Leong PK; Thorner P; Yeger H; Ng K; Zhang Z; Squire J
    Lab Invest; 1993 Jul; 69(1):43-50. PubMed ID: 8331897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique.
    Nathanson DR; Nash GM; Chen B; Gerald W; Paty PB
    J Am Coll Surg; 2003 Sep; 197(3):419-25. PubMed ID: 12946797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
    Crabbe DC; Peters J; Seeger RC
    Diagn Mol Pathol; 1992 Dec; 1(4):229-34. PubMed ID: 1342970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations.
    Squire JA; Thorner P; Marrano P; Parkinson D; Ng YK; Gerrie B; Chilton-Macneill S; Zielenska M
    Mol Diagn; 1996 Dec; 1(4):281-289. PubMed ID: 10462574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
    Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
    Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
    Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
    Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F; Shen T; Prichard JW
    Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.